Ra Capital Management, L.P. Acquires 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. bought 341,742 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, March 7th, Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock. The stock was bought at an average price of $31.02 per share, with a total value of $3,418,590.12.

Janux Therapeutics Trading Down 0.4 %

JANX stock traded down $0.11 on Friday, hitting $30.64. The company had a trading volume of 653,704 shares, compared to its average volume of 815,271. The stock’s 50-day simple moving average is $41.74 and its 200 day simple moving average is $47.55. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23. Janux Therapeutics, Inc. has a 12-month low of $29.63 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors have recently bought and sold shares of the business. Plato Investment Management Ltd raised its stake in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares during the period. Russell Investments Group Ltd. boosted its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares during the period. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics in the 4th quarter worth about $59,000. Avanza Fonder AB purchased a new position in shares of Janux Therapeutics during the fourth quarter worth approximately $139,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at approximately $159,000. Institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on JANX shares. Leerink Partners upped their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics currently has an average rating of “Buy” and an average price target of $88.00.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.